Shares of US biotech CNS Pharmaceuticals (Nasdaq: CNSP) gained 4.1% to $4.33 yesterday, after revealing that it has completed an agreement with Houston Pharmaceuticals Inc (HPI) to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as berubicin.
CNS' licensing agreement with HPI grants the company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. Financial terms of the deal were not disclosed. In its agreement with HPI, the company acquired multiple US patents for berubicin. CNS intends to apply for orphan drug status for berubicin with the Food and Drug Administration for the treatment of malignant glioma.
"We believe our acquisition of the rights to berubicin represents an important milestone in our pursuit to develop therapies for the treatment of glioblastoma, a type of brain cancer which is currently considered incurable," stated CNS chief executive John Climaco, adding: "Our agreement with HPI expands our IP protection and provides us with developmental protection worldwide while we seek orphan drug status. We are excited to continue the clinical development of berubicin and believe its promising tolerability and efficacy results are a testament to its therapeutic potential as a novel anthracycline agent."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze